SOURCE: PCI Synthesis

PCI Synthesis

September 14, 2016 09:17 ET

PCI Synthesis Obtains DEA Registration for Controlled Substance Development and Manufacturing

Expands Capabilities to Handle cGMP Development for Schedule II, III, IV and V

NEWBURYPORT, MA--(Marketwired - Sep 14, 2016) -  PCI Synthesis (www.pcisynthesis.com), a drug substance Contract Manufacturing Organization (CMO) of new chemical entities (NCEs) and generic active pharmaceutical ingredients (APIs), today announced that it has obtained registration and certification from the U.S. Drug Enforcement Administration (DEA) to handle Schedule II, III, IV and V controlled substances.

With DEA registration, the company will be able to work on behalf of clients on projects that are considered controlled substances or the raw materials that are used to produce them. The ability to handle controlled substances is becoming a much needed requirement as the company expands its offerings to the Life Science sector.

"Expanding the type of substances we can work with positions PCI Synthesis to meet the growing demand for new molecules that make use of the medical value of controlled substances," said Edward S. Price, president of PCI Synthesis. "As a cGMP facility that has DEA certification, we can assure our sponsors that the work we do can take them from discovery all the way through commercialization."

In preparation for these new substances, the company has invested in new systems, processes, and training so that it can manufacture controlled substances in its Newburyport facility. It has also conducted an audit by a third party to ensure PCI Synthesis is in compliance required to earn and maintain its DEA registration.

"DEA certification for these kinds of controlled substances opens a new dimension for PCI Synthesis in terms of the types of projects the company can pursue," said Jim Bruno at Chemical and Pharmaceutical Solutions, a New Jersey-based consultancy. "Once PCI Synthesis receives the DEA certification, it will be able to do R&D and move those projects into commercial production."

PCI Synthesis, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, earlier this year announced that its commercially approved products portfolio now includes nine commercial products that either have or are imminently receiving FDA approval for sale in the U.S. The company has more than 17 API and other advanced materials products in its commercial pipeline.

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Contact Information

  • Contact:
    Linda Pendergast-Savage
    Birnbach Communications
    508-224-7905
    Email Contact